MT1A and neoplasm: The results indicated high consistency with clinical gold standard, with superior sensitivity and specificity compared with existing studies and commonly used tumor markers, particularly for early-stage EC at stage 0 and I. The approach of combining the detection of MT-1A, Epo, and Septin9 gene methylation for EC diagnosis, which we believe was introduced by this study, is a strategy not previously documented to our knowledge.